Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Shareholder Meeting (November 2021)
22 slides from Cynata Therapeutics's shareholder meeting presentation, Nov 16, 2021
Slide 1: Chairman's 2021 AGM Address
ASX ANNOUNCEMENT 16 November 2021 Chairman’s 2021 AGM Address For personal use only Good morning everyone and welcome to the 2021 Annual General Meeting of Cynata Therapeutics Ltd. I am Geoff Brooke, the Non-Executive Chairman, and I am joined today by Dr Ross Macdonald, the Managing Director and Ch
Slide 2: Chairman's 2021 AGM Address (continued)
into virtually any cell in the human body. The Cymerus™ MSC manufacturing process actively addresses current challenges associated with conventional methods of producing MSC-based therapies that have been identified by the US FDA, including cell heterogeneity arising from a reliance on multiple dono
Slide 3: Chairman's 2021 AGM Address (continued)
models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the d
Slide 4: A Next Generation Stem Cell Therapeutics Company
For personal use only A Next Generation Stem Cell Therapeutics Company AGM Presentation 16 November 2021
Slide 5: Important information
Important information Summary information ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, ‘potential’ and other similar This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries expressions. The forward looking statem
Slide 6: Key Highlights: FY 2021 Clinical & Pre-clinical
Key Highlights: FY 2021 Clinical & Pre-clinical For personal use only Commenced and Commenced Ethics approval Completed Phase 1 advanced enrolment in enrolment and received to commence GvHD trial two-year Phase 3 osteoarthritis expanded recruitment a clinical trial in follow up with positive trial c
Slide 7: Key Highlights: FY 2021 Commercial & Corporate
For personal use only Key Highlights: FY 2021 Commercial & Corporate Strengthened the Raised $18.3m in Signed a licence Strengthened IP Board with the Signed a new strategic capital led by $10m agreement with portfolio, with patents appointment of Dr. partnership agreement cornerstone TekCyte for th
Slide 8: Strategic partnership with Fujifilm provides commercial benefits
Strategic partnership with Fujifilm provides commercial benefits Fujifilm remains very supportive of Cynata through new SPA For personal use only 1 Key SPA terms • US$5m fee payable by Fujifilm to Cynata • Cynata regained all development and commercialisation rights to CYP-001 • Fujifilm agreed to f
Slide 9: Conventional vs. Cynata's Cymerus MSC manufacturing process
Conventional vs. Cynata’s Cymerus MSC manufacturing process Cells donated Conventional process MSCs For personal use only The current Cells from MSC isolation MSC expansion Cell therapy product multiple donors conventional manufacturing process is sub optimal Substantial variability Limited quantity
Slide 10: Cynata's technology addresses FDA concerns
Cynata’s technology addresses FDA concerns Cynata’s Cymerus process actively addresses current inefficiencies of MSC manufacturing, de-risking clinical development in the US For personal use only Traditional MSC manufacturing is sub-optimal, Cynata’s technology is optimal resulting in substantial fu
Slide 11: Cynata has an advanced and diverse product pipeline
Cynata has an advanced and diverse product pipeline Compelling safety results from Phase 1 GvHD trials1 and positive preclinical data in each target indication have accelerated the pipeline For personal use only Pre-clinical Phase 1 / Phase 2 Phase 3 Osteoarthritis Funded by NHMRC (SCUlpTOR) GvHD Re
Slide 12: GvHD | Ground-breaking Phase 1 clinical trial results
GvHD | Ground-breaking Phase 1 clinical trial results Cynata’s Phase 1 GvHD trial met all safety and efficacy endpoints and broke ground by being the world’s first clinical trial of an allogeneic iPSC-derived product For personal use only Key results1 demonstrate safety and efficacy of Cymerus MSCs
Slide 13: Accelerate US development strategy for GvHD
Accelerate US development strategy for GvHD Cynata is aiming to progress a Phase 2 GvHD clinical trial in the US, after regaining clinical and commercial rights to CYP-001 in GvHD For personal use only Orphan Drug Phase 1 trial SPA with Phase 2 trial Engage with Commence Designation results Fujifilm
Slide 14: SCUlpTOR | Osteoarthritis Phase 3 clinical trial
SCUlpTOR1 | Osteoarthritis Phase 3 clinical trial Clinical trial underway, sponsored by the University of Sydney and funded by an NHMRC project grant For personal use only • Osteoarthritis (OA) occurs when the cartilage in a joint wears away Key Milestones Osteoarthritis • Causes pain, inflammation,
Slide 15: MEND | Phase 1/2 clinical trial in respiratory distress
MEND1 | Phase 1/2 clinical trial in respiratory distress Patient recruitment underway, following expansion of patient population to increase pool of potential subjects For personal use only • Respiratory Failure is a collection of signs and symptoms which Key Milestones Respiratory collectively can
Slide 16: DFU | Phase 1 clinical trial
DFU | Phase 1 clinical trial Recruitment is expected to commence in 2H CY21, following ethics committee1 approval For personal use only Key Milestones Diabetic Foot • DFU are sores on the feet of patients with diabetes (also known as Ulcers (DFU) diabetic wounds) Sign licence Completed with TekCyte
Slide 17: Multiple targets to expand the clinical development pipeline
Multiple targets to expand the clinical development pipeline A Phase 2 trial in GvHD will be an important late-stage addition to Cynata’s robust clinical pipeline For personal use only Crohn’s Disease Others Osteoarthritis (funded by NHMRC) Fistula Coronary Artery Disease Potential future Phase 3 ta
Slide 18: Significant market opportunities
Significant market opportunities Cynata’s rich pipeline targets a range of indications with attractive market dynamics For personal use only Target area Trial Phase Market opportunity 1 Osteoarthritis (OA) Phase 3 underway US$11.6bn Acute Respiratory Distress Syndrome (ARDS) Phase 1/2 underway US$8,
Slide 19: Near term catalysts
Near term catalysts Cynata is in a strong position to advance development of its proprietary Cymerus platform technology For personal use only Complete start up activities for Phase 1 DFU trial, and... Commence recruitment in Phase 1 DFU trial Complete recruitment of 24 patients in Phase 2 MEN
Slide 20: Board & management
Board & management Highly skilled and experienced senior leadership team with decades of experience in biotechnology For personal use only Dr Geoff Brooke Dr Ross Macdonald Dr Kilian Kelly Dr Jolanta Airey Chairman Managing Director / CEO Chief Operating Officer Chief Medical Officer • 30+ years exp
Slide 21: Summary
Summary Cynata is a clinical stage biotech developing its proprietary CymerusTM platform technology for the scalable manufacture of mesenchymal stem cell (MSC) therapeutic products to treat serious disorders For personal use only Unique Strong safety Multiple Large Significant manufacturing and effi
Slide 22: Thank You & Questions
For personal use only Thank You & Questions Cynata Therapeutics Limited Contact details: Level 3 100 Cubitt Street ross.macdonald@cynata.com Cremorne Victoria 3121 www.cynata.com Australia Authorised for release by the Board
Cynata Therapeutics — Shareholder Meeting (November 2021) on 6ix